Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10734628 | 0.85 | RAB9A (0.37) | ACVR1TLR7DPP4DPP8PDE10A | |
| SCHEMBL204996 | 0.78 | KDM4E (0.42) | KDM4EGPR3HSD17B10HPGDUSP5 | |
| SCHEMBL4703998 | 0.78 | KDM4E (0.42) | KDM4EGPR3HSD17B10HPGDUSP5 | |
| SCHEMBL5823463 | 0.78 | KDM4E (0.42) | KDM4EGPR3TLR7HSD17B10HPGD | |
| SCHEMBL5092806 | 0.78 | KDM4E (0.42) | KDM4EGPR3HSD17B10HPGD | |
| SCHEMBL9207616 | 0.77 | HTR1A (0.41) | IP6K1 | |
| SCHEMBL8721713 | 0.77 | KDM4E (0.39) | KDM4EGPR3TLR7HSD17B10HPGD | |
| SCHEMBL2707327 | 0.77 | KDM4E (0.39) | KDM4EGPR3TLR7HSD17B10HPGD | |
| SCHEMBL9601955 | 0.77 | SMN1; SMN2 (0.42) | KDM4EGPR3TLR7 | |
| SCHEMBL1486425 | 0.76 | KDM4E (0.41) | KDM4EGPR3HSD17B10HPGDUSP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20070166384-A1 | Methods , composition and preparations for delivery of immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| EP-0329073-B1 | 2-Substituted carbonylimidazo[4,5-c]quinolines | SHIONOGI & CO (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-4940714-A | 2-substituted carbonylimidazo[4,5-c]quinolines | SHIONOGI & CO., LTD. (JP) | 1990-07-10 | — | — | US | disclosed |
| EP-0329073-A2 | 2-Substituted carbonylimidazo[4,5-c]quinolines | SHIONOGI & CO., LTD. (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | LRRK2, PARK7, SNCA | KDM4E 1323/4885GPR3 1281/4885ACVR1 3170/4885 |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | LRRK2, PARK7, SNCA | KDM4E 1167/4885GPR3 1252/4885ACVR1 2875/4885 |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NRAS, BRAF, KRAS | KDM4E 991/4885GPR3 3384/4885ACVR1 1833/4885 |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NRAS, BRAF, KRAS | KDM4E 991/4885GPR3 3384/4885ACVR1 1833/4885 |
| US-20070166384-A1 | Methods , composition and preparations for delivery of immune response modifiers | TLR3, MYD88, IFNG | KDM4E 3888/4885GPR3 1942/4885ACVR1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.